Featured Research

from universities, journals, and other organizations

Deficient protein GM-CSF production found to impair gut's immune tolerance

Date:
March 13, 2014
Source:
Mount Sinai Medical Center
Summary:
The protein GM-CSF plays a critical role in maintaining immune tolerance in the gut, with defects in the protein increasing the susceptibility to inflammatory bowel diseases (IBD), according to a new mouse study. IBD is a severe intestinal disease characterized by chronic intestinal inflammation that results from a dysregulated immune response to microbes and food antigens.

The protein GM-CSF plays a critical role in maintaining immune tolerance in the gut, with defects in the protein increasing the susceptibility to inflammatory bowel diseases (IBD), according to a new mouse study by a team of researchers from the Icahn School of Medicine at Mount Sinai. IBD is a severe intestinal disease characterized by chronic intestinal inflammation that results from a dysregulated immune response to microbes and food antigens.

Writing in the peer reviewed journal Science published online March 13, 2014, the research team writes that this advances our understanding of how commensal microbes can regulate intestinal immunity and should pave the wave for identifying new drug targets.

“These results are highly relevant to clinical inflammatory bowel diseases because GMSCF-impaired function is now emerging as one of the best predictors of IBD severity,” said the study’s senior author, Miriam Merad, MD, PhD, Professor in the Department of Oncological Sciences, the Tisch Cancer Institute and the Immunology Institute, at the Icahn School of Medicine at Mount Sinai.

GM-CSF is a cytokine that promotes the development and function of a group of gut resident macrophages and dendritic cells. Although GMCSF is mostly known for its role in inflammation, Dr. Merad’s laboratory discovered that GM-CSF is produced in the normal gut by specialized cells called innate lymphocyte cells (ILCs) in response to microbiota signals. Strikingly, they found that microbiota-induced GM-CSF was required to imprint gut tissue resident macrophages and dendritic cells with regulatory function that was critical to protect against inflammation of the gut. Deletion of the GM-CSF gene in the mouse led to reduction and impaired regulatory function of gut tissue macrophages and dendritic cells which compromised induction of tolerance to food antigens and increased mice susceptibility to IBD.

“These results represent a significant advance in our understanding of how commensal microbes can regulate host intestinal immune responses and suggest that the identification of downstream targets in macrophages and dendritic cells along the GM-CSF axis can help the rationale design of novel strategies for the treatment of IBD patients with defective GM-CSF function,” explained Dr. Merad.

Drs. Merad and Mortha are now developing a multiscale approach to identify GM-CSF downstream targets using macrophages and dendritic cells isolated from GM-CSF deficient mice and exposed to recombinant GMCSF. The regulatory function of novel targets will be validated in collaboration with Judy H. Cho, MD, Ward-Coleman Professor of Medicine and Genetics and Genomic Sciences, and Assistant Chief of Research in the Gastrointestinal Division, and Jean Federic Colombel, MD, Professor of Medicine and Director of the Leona M. and Harry B. Helmsley Charitable Trust Inflammatory Bowel Disease Center, at they Icahn School of Medicine at Mount Sinai. They will study human macrophages and dendritic cells isolated from IBD patients with defective GM-CSF function, “The approach represents a step forward in personalizing how we treat patients with IBD,” said Dr. Colombel.


Story Source:

The above story is based on materials provided by Mount Sinai Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. A. Mortha, A. Chudnovskiy, D. Hashimoto, M. Bogunovic, S. P. Spencer, Y. Belkaid, M. Merad. Microbiota-Dependent Crosstalk Between Macrophages and ILC3 Promotes Intestinal Homeostasis. Science, 2014; DOI: 10.1126/science.1249288

Cite This Page:

Mount Sinai Medical Center. "Deficient protein GM-CSF production found to impair gut's immune tolerance." ScienceDaily. ScienceDaily, 13 March 2014. <www.sciencedaily.com/releases/2014/03/140313142451.htm>.
Mount Sinai Medical Center. (2014, March 13). Deficient protein GM-CSF production found to impair gut's immune tolerance. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/03/140313142451.htm
Mount Sinai Medical Center. "Deficient protein GM-CSF production found to impair gut's immune tolerance." ScienceDaily. www.sciencedaily.com/releases/2014/03/140313142451.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins